



1600

RAW SEQUENCE LISTING

DATE: 02/19/2003

PATENT APPLICATION: US/09/856,070A

TIME: 14:29:15

Input Set : A:\GJE-67.seq.ST25.txt

Output Set: N:\CRF4\02192003\I856070A.raw

3 41100 APPLICANT: Holms, Rupert D.
 4 41100 TITLE OF INVENTION: Pegylatory/Unfolding Peptides of Ezrin
 5 41100 FILE REFERENCE: GJE-67
 6 41400 CURRENT APPLICATION NUMBER: 09/856,070A
 10 41410 CURRENT FILING DATE: 2001-05-17
 11 41100 PRIOR APPLICATION NUMBER: PCT/GB00/03566
 13 41110 PRIOR FILING DATE: 2000-09-15
 15 41500 PRIOR APPLICATION NUMBER: 9921881.0
 16 41510 PRIOR FILING DATE: 1999-09-17
 18 41600 NUMBER OF SEQ ID NOS: 25
 20 41700 SOFTWARE: PatentIn version 3.1

21 42100 SEQ ID NO: 1
 23 42110 LENGTH: 32
 24 42110 TYPE: PRT
 25 42110 ORGANISM: Artificial Sequence
 27 42110 FEATURE:
 1- 42110 OTHER INFORMATION: Heparin receptor peptide

28 44000 SEQUENCE: 1
 31 Ala Arg Glu Glu Lys His Gln Lys Gln Leu Glu Arg Gln Gln Leu Glu
 35 1 5 10 15
 36 Thr Glu Lys Lys Arg Arg Gln Thr Val Glu Arg Glu Lys Glu Gln Met
 40 20 25 30

41 42110 SEQ ID NO: 2
 43 42110 LENGTH: 14
 44 42110 TYPE: PRT
 45 42110 ORGANISM: Artificial Sequence
 47 42110 FEATURE:
 48 42110 OTHER INFORMATION: Heparin receptor peptide
 49 42110 FEATURE:

44 42110 NAME/KEY: MISC_FEATURE
 51 42110 LOCATION: (14)..(14)
 52 42110 OTHER INFORMATION: Xaa = Tyr(P)
 54 44000 SEQUENCE: 2

W--> 56 Met Arg Glu Lys Glu Glu Leu Met Leu Arg Leu Gln Asp Xaa Glu Glu
 57 1 5 10 15
 58 Lys Thr Lys Lys Ala Glu Arg Glu Leu Ser Glu Gln Ile Gln Arg Ala
 61 20 25 30
 62 Leu Glu

63 42110 SEQ ID NO: 3
 64 42110 LENGTH: 5
 65 42110 TYPE: PRT
 66 42110 ORGANISM: Artificial Sequence
 67 42110 FEATURE:

ENTERED

RAW SEQUENCE LISTING

DATE: 02/19/2003

PATENT APPLICATION: US/09/856,070A

TIME: 14:29:15

Input Set : A:\GJE-67.seq.ST25.txt

Output Set: N:\CRF4\02192003\I856070A.raw

74 <C23> OTHER INFORMATION: Heparin peptide

75 <C400> SEQUENCE: 3

76 Thr Glu Lys Lys Arg

77 1 5

82 <C10> SEQ ID NO: 4

83 <C11> LENGTH: 4

84 <C12> TYPE: PRT

85 <C13> ORGANISM: Artificial Sequence

86 <C14> FEATURE:

87 <C15> OTHER INFORMATION: Heparin peptide

88 <C400> SEQUENCE: 4

89 Thr Glu Lys Lys Arg Arg Glu Thr Val

90 1 5

96 <C10> SEQ ID NO: 5

97 <C11> LENGTH: 11

98 <C12> TYPE: PRT

99 <C13> ORGANISM: Artificial Sequence

100 <C14> FEATURE:

101 <C15> OTHER INFORMATION: Heparin peptide

102 <C400> SEQUENCE: 5

103 Thr Glu Lys Lys Arg Arg Glu Thr Val Glu Arg

104 1 10

110 <C10> SEQ ID NO: 6

111 <C11> LENGTH: 9

112 <C12> TYPE: PRT

113 <C13> ORGANISM: Artificial Sequence

114 <C14> FEATURE:

115 <C15> OTHER INFORMATION: Heparin peptide

116 <C400> SEQUENCE: 6

117 Lys Lys Arg Arg Glu

118 1 6

124 <C10> SEQ ID NO: 7

125 <C11> LENGTH: 8

126 <C12> TYPE: PRT

127 <C13> ORGANISM: Artificial Sequence

128 <C14> FEATURE:

129 <C15> OTHER INFORMATION: Heparin peptide

130 <C400> SEQUENCE: 7

131 Lys Lys Arg Arg Glu Thr Val Glu

132 1 8

138 <C10> SEQ ID NO: 8

139 <C11> LENGTH: 10

140 <C12> TYPE: PRT

141 <C13> ORGANISM: Artificial Sequence

142 <C14> FEATURE:

143 <C15> OTHER INFORMATION: Heparin peptide

144 <C400> SEQUENCE: 8

145 Lys Lys Arg Arg Glu Thr Val Glu Arg Glu

146 1 10

RAW SEQUENCE LISTING

DATE: 02/19/2003

PATENT APPLICATION: US/09/856,070A

TIME: 14:29:15

Input Set : A:\GJE-67.seq.ST25.txt

Output Set: N:\CRF4\02192003\I856070A.raw

```

153 <210> SEQ ID NO: 9
154 <211> LENGTH: 11
155 <212> TYPE: PRT
156 <213> ORGANISM: Artificial Sequence
157 <214> FEATURE:
158 <215> OTHER INFORMATION: Hepreceptor peptide
160 <400> SEQUENCE: 9
161 Lys Lys Arg Arg Glu Thr Val Glu Arg Glu Lys
162 1 5 10
163 <210> SEQ ID NO: 10
164 <211> LENGTH: 12
165 <212> TYPE: PRT
166 <213> ORGANISM: Artificial Sequence
167 <214> FEATURE:
168 <215> OTHER INFORMATION: Hepreceptor peptide
170 <400> SEQUENCE: 10
171 Lys Lys Arg Arg Glu Thr Val Glu Arg Glu Lys Glu
172 1 5 10
173 <210> SEQ ID NO: 11
174 <211> LENGTH: 9
175 <212> TYPE: PRT
176 <213> ORGANISM: Artificial Sequence
177 <214> FEATURE:
178 <215> OTHER INFORMATION: Hepreceptor peptide
180 <400> SEQUENCE: 11
181 Lys Arg Arg Glu Thr Val Glu Arg
182 1 5 10
183 <210> SEQ ID NO: 12
184 <211> LENGTH: 10
185 <212> TYPE: PRT
186 <213> ORGANISM: Artificial Sequence
187 <214> FEATURE:
188 <215> OTHER INFORMATION: Hepreceptor peptide
190 <400> SEQUENCE: 12
191 Lys Arg Arg Glu Thr Val Glu Arg Glu Lys
192 1 5 10
193 <210> SEQ ID NO: 13
194 <211> LENGTH: 11
195 <212> TYPE: PRT
196 <213> ORGANISM: Artificial Sequence
197 <214> FEATURE:
198 <215> OTHER INFORMATION: Hepreceptor peptide
200 <400> SEQUENCE: 13
201 Lys Arg Arg Glu Thr Val Glu Arg Glu Lys Glu
202 1 5 10
203 <210> SEQ ID NO: 14
204 <211> LENGTH: 9
205 <212> TYPE: PRT
206 <213> ORGANISM: Artificial Sequence

```

RAW SEQUENCE LISTING

DATE: 02/19/2003

PATENT APPLICATION: US/09/856,070A

TIME: 14:29:15

Input Set : A:\GJE-67.seq.ST25.txt

Output Set: N:\CRF4\02192003\I856070A.raw

```

227 <220> FEATURE:
228 <221> OTHER INFORMATION: Heparin peptide
229 <400> SEQUENCE: 14
230 Arg Arg Glu Thr Val
231 1 5
232 <210> SEQ ID NO: 15
233 <211> LENGTH: 9
234 <212> TYPE: PR1
235 <213> ORGANISM: Artificial Sequence
236 <220> FEATURE:
237 <221> OTHER INFORMATION: Heparin peptide
238 <400> SEQUENCE: 15
239 Arg Glu Thr Val Glu Arg Glu Lys Glu
240 1 5
241 <210> SEQ ID NO: 16
242 <211> LENGTH: 9
243 <212> TYPE: PR1
244 <213> ORGANISM: Artificial Sequence
245 <220> FEATURE:
246 <221> OTHER INFORMATION: Heparin peptide
247 <400> SEQUENCE: 16
248 Glu Arg Glu Lys Glu
249 1 5
250 <210> SEQ ID NO: 17
251 <211> LENGTH: 14
252 <212> TYPE: PR1
253 <213> ORGANISM: Artificial Sequence
254 <220> FEATURE:
255 <221> OTHER INFORMATION: Heparin peptide
256 <400> SEQUENCE: 17
257 Glu Arg Glu Lys Glu Gln Met Met Arg Glu Lys Glu Glu Leu
258 1 10
259 <210> SEQ ID NO: 18
260 <211> LENGTH: 9
261 <212> TYPE: PR1
262 <213> ORGANISM: Artificial Sequence
263 <220> FEATURE:
264 <221> OTHER INFORMATION: Heparin peptide
265 <400> SEQUENCE: 18
266 Lys Glu Glu Leu Met
267 1 5
268 <210> SEQ ID NO: 19
269 <211> LENGTH: 13
270 <212> TYPE: PR1
271 <213> ORGANISM: Artificial Sequence
272 <220> FEATURE:
273 <221> OTHER INFORMATION: Heparin peptide
274 <400> SEQUENCE: 19
275 Lys Glu Glu Leu Met Leu Arg Leu Gln Asp Tyr Glu Glu

```

RAW SEQUENCE LISTING

DATE: 02/19/2003

PATENT APPLICATION: US/09/856,070A

TIME: 14:29:15

Input Set : A:\GJE-67.seq.ST25.txt

Output Set: N:\CRF4\02192003\I856070A.raw

```

302 1           5           10
300 <210> SEQ ID NO: 20
301 <211> LENGTH: 13
302 <212> TYPE: PRT
303 <213> ORGANISM: Artificial Sequence
304 <214> FEATURE:
305 <215> OTHER INFORMATION: Heparin peptide
306 <216> FEATURE:
307 <217> NAME/KEY: MISC_FEATURE
308 <218> LOCATION: (1)..(11)
309 <219> OTHER INFORMATION: Xaa = Tyr(P)
310 <210> SEQUENCE: (1)
W--> 322 Lys Glu Glu Leu Met Leu Arg Leu Gln Asp Xaa Glu Glu
311 1           5           10
312 <210> SEQ ID NO: 21
313 <211> LENGTH: 12
314 <212> TYPE: PRT
315 <213> ORGANISM: Artificial Sequence
316 <214> FEATURE:
317 <215> OTHER INFORMATION: Heparin peptide
318 <216> SEQUENCE: (1)
319 Glu Glu Leu Met Leu Arg Leu Gln Asp Tyr Glu Glu
320 1           5           10
321 <210> SEQ ID NO: 22
322 <211> LENGTH: 12
323 <212> TYPE: PRT
324 <213> ORGANISM: Artificial Sequence
325 <214> FEATURE:
326 <215> OTHER INFORMATION: Heparin peptide
327 <216> FEATURE:
328 <217> NAME/KEY: MISC_FEATURE
329 <218> LOCATION: (10)..(10)
330 <219> OTHER INFORMATION: Xaa = Tyr(P)
331 <210> SEQUENCE: (1)
W--> 356 Glu Glu Leu Met Leu Arg Leu Gln Asp Xaa Glu Glu
332 1           5           10
333 <210> SEQ ID NO: 23
334 <211> LENGTH: 11
335 <212> TYPE: PRT
336 <213> ORGANISM: Artificial Sequence
337 <214> FEATURE:
338 <215> OTHER INFORMATION: Heparin peptide
339 <216> SEQUENCE: (1)
340 Glu Leu Met Leu Arg Leu Gln Asp Tyr Glu Glu
341 1           5           10
342 <210> SEQ ID NO: 24
343 <211> LENGTH: 11
344 <212> TYPE: PRT
345 <213> ORGANISM: Artificial Sequence

```

RAW SEQUENCE LISTING ERROR SUMMARY
PATENT APPLICATION: US/09/856,070A

DATE: 02/19/2003
TIME: 14:29:16

Input Set : A:\GJE-67.seq.ST25.txt
Output Set: N:\CRF4\02192003\I856070A.raw

Please Note:

Use of n and/or Xaa have been detected in the Sequence Listing. Please review the Sequence Listing to ensure that a corresponding explanation is presented in the <220> to <223> fields of each sequence which presents at least one n or Xaa.

Seq#:2; Xaa Pos. 14
Seq#:20; Xaa Pos. 11
Seq#:22; Xaa Pos. 10
Seq#:24; Xaa Pos. 9
Seq#:27; Xaa Pos. 3